Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab and Tiragolumab for HPV+ SCC with Detectable ctDNA
NCT06762808Phase 2Withdrawn
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- May 2025
- Primary completion
- Aug 2025
- Modality
- Immune Checkpoint Inhibitors
01
Overview
Phase 2, open-label, single-arm trial of tiragolumab in squamous cell carcinoma (SCC), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Disease-Free Survival at 1 year. Planned start May 2025; status: withdrawn.
02
Drugs
tiragolumab
03
Conditions
squamous cell carcinoma (SCC)
Beyond the preview
Go deeper on NCT06762808.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06762808.